Singapore, Jan. 6 -- Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue regeneration, has announced a strategic collaboration with Nucelion Therapeutics, a specialised contractresearch,development and manufacturing organisation (CRDMO),to expand manufacturing capabilities for Pandorum's exosome-based therapeutic platform across the Asia-Pacific (APAC) region.

This strategic collaboration aligns with a shared vision, asPandorum's asset(s)progress toward clinical trials. By leveraging Nucelion Therapeutics' manufacturing capabilities, the partnership supports regional supply and regulatory readiness, marking a strategic step forward.Furthermore, it reaffirms Ind...